September 02, 2021
The U.S. Food and Drug Administration (FDA) announced this week that its vaccine advisers will meet September 17 to provide recommendations about COVID-19 booster doses.
The advisory meeting will provide an independent evaluation about the need for additional doses of the available COVID-19 vaccines, FDA officials said. The meeting comes three days ahead of the White House’s September 20 plan to make Pfizer-BioNTech and Moderna COVID-19 booster doses available.
“A transparent, thorough, and objective review of the data by the FDA is critical so that the medical community and the public continue to have confidence in the safety and effectiveness of COVID-19 vaccines,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Research and Evaluation. “The FDA will review the supplemental application as expeditiously as possible, while still doing so in a thorough and science-based manner.”
Here’s what you need to know about the next steps for the White House’s booster plan:
The White House’s booster plan accompanies an ongoing effort to encourage people who have not received the COVID-19 vaccine to make an appointment. The spread of the Delta variant has made it even more important to increase vaccination rates, with all Pennsylvania counties reporting “high” or “substantial” spread of the virus.
Information about the COVID-19 vaccine is available online.
HAP will continue to monitor COVID-19 public health developments and provide updates to members. For more information, contact Robert Shipp III, PhD, BSN, RN, NEA-BC, HAP’s vice president, population health and clinical affairs.
Tags: Public Health | COVID-19
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.